Alan Hirzel

Next generation protein interrogation powered by nanoneedles, enabling early disease detection, prognostic monitoring and biomarker discovery on a single chip.

Valora Therapeutics Inc. (Valora) is a pre-clinical stage biopharmaceutical company based in San Diego, California, USA, pioneering a new biologic platform invented by Nobel Laureate Dr. Carolyn Bertozzi (Stanford). Our proprietary platform technology enables the engineering of chimeric antibodies to unlock new mechanisms of immune signaling and activity, paving the way for transformative therapies in oncology, immune diseases, and beyond.

Cera is a digital-first home healthcare company that harnesses technology to bring care directly to homes, transforming the healthcare landscape by providing higher quality services at a fraction of the cost. Cera’s carers and nurses now provide technology-enabled services covering a population of 30 million people across the UK and Germany. This amounts to 60,000 patient appointments a day in the community, on behalf of governments, insurers, and the NHS - equivalent in capacity to almost 100 hospitals. With 150-fold growth in the past four years, Cera is one of Europes fastest-growing businesses, recently passing $300m in annualised revenues. Cera has also gathered one of the largest home healthcare datasets globally, powering the development of cutting-edge AI products that have reduced hospitalisations by up to 70%. Consistently ranked as the UKs top HealthTech company, Cera’s pioneering approach has been recognised by numerous industry awards including Home Care Awards’ Most Outstanding Home Care Provider, a top-ten position in Deloitte Fast 50 for three consecutive years, and the prestigious Great British Entrepreneur of the Year award in 2023. Cera was co-founded by entrepreneur, physician and policy expert Dr Ben Maruthappu MBE. Its Advisory Board is Chaired by Sir David Behan, the former CEO of the Care Quality Commission.

ScubaTx is developing a new breakthrough platform for the preservation of human organs.

Healx is a mission-driven technology company pioneering the next generation of drug discovery in order to bring novel, effective treatments to rare disease patients around the world. There are more than 10,000 known rare diseases that affect 400 million people across the globe, but only 5% of those conditions have an approved treatment. By combining frontier AI technology with deep drug discovery and development expertise, Healx can accelerate the pace, increase the scale and improve the chance of success of rare disease treatment development in order to meet this huge unmet need and have unprecedented patient impact.

Advent is a leading global private equity investor committed to working in partnership with management teams, entrepreneurs, and founders to help transform businesses. Since our founding in 1984, we have developed specialist market expertise across our five core sectors: business & financial services, consumer, healthcare, industrial, and technology. As one of the largest privately-owned partnerships, our 600+ colleagues across five continents leverage the full ecosystem of Advent’s global resources to support and guide our portfolio companies as they seek to achieve their strategic goals. To learn more, visit adventinternational.com.

Battery invests in potentially cutting-edge, category-defining businesses in markets including application software, IT infrastructure technologies, consumer-internet and mobile services, and industrial technologies. Founded in 1983, the firm backs companies at stages ranging from seed to growth and private equity, and invests globally from offices in Boston, Silicon Valley, New York, London and Israel. For a full list of our portfolio companies, please visit https://www.battery.com/list-of-all-companies/.

Start and scale here. augscala supports executives and investors starting and scaling companies in the life sciences, diagnostics, pharmaceuticals, agbiotech, and food industries.

Next generation protein interrogation powered by nanoneedles, enabling early disease detection, prognostic monitoring and biomarker discovery on a single chip.

Valora Therapeutics Inc. (Valora) is a pre-clinical stage biopharmaceutical company based in San Diego, California, USA, pioneering a new biologic platform invented by Nobel Laureate Dr. Carolyn Bertozzi (Stanford). Our proprietary platform technology enables the engineering of chimeric antibodies to unlock new mechanisms of immune signaling and activity, paving the way for transformative therapies in oncology, immune diseases, and beyond.